Sign In
Buy SAN
$12.47
+0.310 (+2.55%)
At Close: Jun 04, 2026
Communiqué de presse: La FDA approuve Dupixent® (dupilumab) – premier médicament pour le traitement de l’œsophagite à éosinophiles de l’adulte et de l’enfant à partir de 12 ans
07:15pm, Friday, 20'th May 2022 GlobeNewswire Inc.
La FDA approuve Dupixent® (dupilumab) – premier médicament pour le traitement de l’œsophagite à éosinophiles de l’adulte et de l’enfant à partir de 12 ans
Baron Fintech Fund Q1 2022 Shareholder Letter
04:55am, Wednesday, 18'th May 2022 Seeking Alpha
In the quarter ended March 31, 2022, Baron FinTech Fund (the “Fund”) fell 16.67% (Institutional Shares). Click here to read the full fund letter.
Implied Volatility Surging for Banco Santander (SAN) Stock Options
05:28pm, Tuesday, 17'th May 2022 Zacks Investment Research
Investors need to pay close attention to Banco Santander (SAN) stock based on the movements in the options market lately.
Is Banco Santander (SAN) a Great Value Stock Right Now?
01:40pm, Tuesday, 17'th May 2022 Zacks Investment Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Is Banco Santander (SAN) a Great Value Stock Right Now?
11:17am, Tuesday, 17'th May 2022
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Sarclisa® (isatuximab) en association permet d’obtenir un allongement sans précédent la survie médiane sans progression des patients atteints d’un myélome multiple en rechute traités par un
Press Release: Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy
07:30am, Sunday, 15'th May 2022 GlobeNewswire Inc.
Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy
Is WisdomTree Europe Hedged Equity ETF (HEDJ) a Strong ETF Right Now?
10:20am, Wednesday, 11'th May 2022 Zacks Investment Research
Smart Beta ETF report for HEDJ
Communiqué de presse: De nouvelles analyses des données relatives au nirsevimab confortent son efficacité contre le VRS
06:00am, Wednesday, 11'th May 2022 GlobeNewswire Inc.
De nouvelles analyses des données relatives au nirsevimab confortent son efficacité contre le VRS
Press Release: New nirsevimab data analyses reinforce efficacy against RSV
06:00am, Wednesday, 11'th May 2022 GlobeNewswire Inc.
New nirsevimab data analyses reinforce efficacy against RSV
Tracking Ken Fisher's Fisher Asset Management Portfolio - Q1 2022 Update
05:44am, Saturday, 07'th May 2022 Seeking Alpha
Ken Fisher’s 13F portfolio value decreased from ~$179B to ~$165B in Q1 2022. Find more details here...
Communiqué de presse : Foundation S, nouveau fer de lance du mécénat de Sanofi
10:00am, Wednesday, 04'th May 2022 GlobeNewswire Inc.
Press Release: Foundation S: Sanofi’s new philanthropic spearhead
10:00am, Wednesday, 04'th May 2022 GlobeNewswire Inc.
Communiqué de presse : Assemblée Générale Annuelle du 3 mai 2022
05:00pm, Tuesday, 03'rd May 2022 GlobeNewswire Inc.
